author-photo

Maen A. Hussein

Sarah Cannon Research Institute

16

Papers

735

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies

2021 Cancer management and research
Show All
- Source
- Cite
- Save
Citations (0)
MO01.42 Myelopreservation with Trilaciclib Regardless of Risk of Chemotherapy-Induced Febrile Neutropenia and/or Anemia or Red Blood Cell Transfusions

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (1)
541P Ezabenlimab (BI 754091), an anti-PD-1 antibody, in combination with BI 836880, a VEGF/Ang2-blocking nanobody, in patients (pts) with previously treated advanced solid tumours

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
MO01.40 Trilaciclib has Myelopreservation Benefits in Patients with Small Cell Lung Cancer Treated with Chemotherapy, Irrespective of Age

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study.

2020 Advances in Therapy
Show All
- Source
- Cite
- Save
Citations (18)
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous Non-Small-Cell Lung Cancer (IMpower131): Results From a Randomized Phase III Trial.

2020 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (120)
Real-world practice patterns and barriers to quality care in acute myeloid leukemia (AML).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Real-world practice patterns in follicular lymphoma (FL) care at community oncology centers.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

2019 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (438)
Safety, Efficacy, and Patient-reported Health-related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged ≥70 Years or with Poor Performance Status (CheckMate 153)

2019 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (77)